Barbara J Mason, David Estey, Amanda Roberts, Giordano de Guglielmo, Olivier George, John Light, Mike Stoolmiller, Susan Quello, Michael Skinner, Farhad Shadan, Adnan Begovic, Mark C Kyle, R Adron Harris
Alcohol Use Disorder (AUD) is a chronic relapsing disorder affecting an estimated 283 million individuals worldwide, with substantial health and economic consequences. Peroxisome proliferator-activated receptors (PPARs), particularly PPAR-α and PPAR-γ, have shown promise in preclinical studies as potential therapeutic targets for AUD. In this human laboratory study, we aimed to translate preclinical findings on the PPAR-α agonist fenofibrate to a human population with current AUD. We hypothesized that, relative to placebo, fenofibrate at the highest FDA-approved dose of 145 mg/d would attenuate responsiveness to in vivo alcohol cues in the lab and reduce drinking under natural conditions...
March 2024: Neurobiology of Stress